Stability of Deferoxamine Peritoneal Dialysate Solutions

Schafer A.I. , Cheron R.G. , Dluhy R. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319–24.

Alfrey A.C. Dialysis encephalopathy. Clin Nephrol 1985; 24: SI5–S19.

Fleming L.W. , Stewart W.K. , Fell G.S. The effect of oral aluminum therapy on plasma aluminum levels in patients with chronic renal failure in an area with low water aluminum. Clin Nephrol 1982; 17: 222–7.

Wolfe L. , Olivieri N. , Sallan D. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312: 1600–3.

Navarro J.A. , Granadillo V.A. , Rodriguez-Iturbe B. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy. Clin Nephrol 1991; 35: 213–17.

Falk R.J. , Mattern W.D. , Lamanna R.W. Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine. Kidney Int 1983; 24: 11012.

Andreoli S.P. , Cohen M. Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD. Kidney Int 1989; 35: 1330–5.

Payton C.D. , Junor B.J.R. , Fell G.S. Successful treatment of aluminum encephalopathy by intraperitoneal desferrioxamine (letter). Lancet 1984; i: 1132–3.

Andreoli S.P. , Dunn D. , DeMyer W. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis. J Pediatr 1985; 107: 760–3.

Schwartz R.D. Chronic peritoneal dialysis: mechanical and infectious complications. Nephron 1985; 40: 2937.

Product information, Desferal mesylate, C84–48 (Rev 12/84), Ciba Pharmaceutical Co., Summitt. New Jersey, U.S.A.

Koren G. , Tesoro A. , Leeder J.S. Stability of aqueous solutions of deferoxamine. Can J Hosp Pharm 1990; 43: 57–60.